Adicet Bio Inc.
0.90
-0.01 (-1.01%)
At close: Jan 15, 2025, 11:53 AM
undefined%
Bid 0.89
Market Cap 73.95M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.7
PE Ratio (ttm) -0.53
Forward PE n/a
Analyst Buy
Ask 0.91
Volume 80,940
Avg. Volume (20D) 597,731
Open 0.92
Previous Close 0.91
Day's Range 0.89 - 0.94
52-Week Range 0.81 - 3.62
Beta undefined

About ACET

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes AD...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2018
Employees 143
Stock Exchange NASDAQ
Ticker Symbol ACET

Analyst Forecast

According to 4 analyst ratings, the average rating for ACET stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 457.17% from the latest price.

Buy 75.00%
Hold 25.00%
Sell 0.00%
Stock Forecasts
3 months ago · Source
+6.43%
Adicet Bio shares are trading higher after the com... Unlock content with Pro Subscription
6 months ago · Source
+9.35%
Adicet Bio shares are trading higher after the company announced that the FDA granted it Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma.